Table 2.
Anterior vs. posterior genitourinary function and quality of life
| Baseline | 3 months | 6 months | 12 months | Segment difference Baseline/6 months |
Different treatment impact Anterior vs. Posterior |
|
|---|---|---|---|---|---|---|
| Anterior | (n=18) | (n=17) | (n=17) | (n=4) | ||
| Posterior | (n=39) | (n=39) | (n=35) | (n=20) | ||
| AUA | ||||||
| Anterior | 6 (3–14) | 6 (3–11) | 4 (3–10) | 4 (2–5) | No (P = 0.55) | No (P = 0.97, |
| Posterior | 6 (3–12) | 7 (3–10) | 5 (2–11) | 4 (2–11) | No (P = 0.19) | E= −0.05, CI ±2.5) |
|
| ||||||
| EPIC urinary | ||||||
| Anterior | 93 (72–98) | 89 (69–96) | 94 (79–98) | 92 (82–97) | No (P = 0.68) | No (P = 0.83, |
| Posterior | 89 (81–98) | 92 (81–98) | 92 (83–98) | 94 (85–98) | No (P = 0.24) | E= −0.71, CI ±6.6) |
|
| ||||||
| EPIC sexual | ||||||
| Anterior | 60 (25–82) | 52 (29–71) | 46 (14–79) | 27 (2–79) | Yes (P = 0.03) | No (P = 0.41, |
| Posterior | 67 (48–81) | 47 (31–74) | 49 (29–69) | 42 (19–76) | Yes (P = 0.008) | E= −4.1, CI ±9.6) |
|
| ||||||
| EPIC bowel | ||||||
| Anterior | 96 (92–100) | 96 (93–98) | 96 (91–99) | 93 (87–99) | No (P = 0.79) | No (P = 0.80, |
| Posterior | 96 (93–98) | 96 (89–100) | 96 (89–100) | 97 (92–100) | No (P = 0.70) | E= 0.51, CI ±3.9) |
|
| ||||||
| SF-12 physical | ||||||
| Anterior | 55 (44–56) | 55 (48–56) | 55 (40–57) | 57 (43–58) | No (P = 0.64) | No (P = 0.74, |
| Posterior | 56 (52–56) | 55 (52–57) | 55 (52–57) | 55 (52–57) | No (P = 0.35) | E= −0.71, CI ±4.1) |
|
| ||||||
| SF-12 mental | ||||||
| Anterior | 56 (39–58) | 56 (50–58) | 56 (40–60) | 53 (48–60) | No (P = 0.80) | No (P = 0.64, |
| Posterior | 56 (50–58) | 57 (53–59) | 56 (48–58) | 57 (56–59) | No (P = 0.45) | E= 1.1, CI ±4.4) |
Data are presented as median (interquartile range).
AUA, American Urological Association; E, the effect size of anterior vs. posterior; CI, confidence interval (represents 47.5% deviation from the mean); EPIC, expanded prostate cancer index composite; SF-12, short form of health survey.